Bluejay Diagnostics, Inc.

BJDX

Healthcare Medical Devices

Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.

EPS
+80.1%
Free cash flow
+20.1%

Quarter to June 2026, against a year earlier

2.35 0.16 +7.31%
Market cap
$2.6M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.8×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(98.89%) (171.56%) (117.02%) (126.19%)

+8 more TTM periods

ROA
(81.07%) (126.94%) (99.42%) (103.45%)
ROIC
0.00% (881.17%) (536.22%) (714.15%)
Return on Tangible Assets
(77.83%) (169.10%) (116.49%) (190.40%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(3.00) (6.75) (14.47) (15.37)
Free Cash Flow
(6.24) (6.65) (6.50) (6.05)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026